Balchem Co. (NASDAQ:BCPC – Get Rating) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totalling 375,600 shares, a drop of 23.5% from the March 15th total of 490,900 shares. Approximately 1.2% of the company’s stock are sold short. Based on an average daily trading volume, of 131,300 shares, the days-to-cover ratio is currently 2.9 days.
Shares of BCPC opened at $133.42 on Monday. The company has a current ratio of 2.24, a quick ratio of 1.61 and a debt-to-equity ratio of 0.14. The company’s fifty day simple moving average is $137.32 and its 200 day simple moving average is $150.78. Balchem has a 1-year low of $119.59 and a 1-year high of $174.29. The company has a market cap of $4.29 billion, a price-to-earnings ratio of 45.23 and a beta of 0.62.
Balchem (NASDAQ:BCPC – Get Rating) last released its quarterly earnings data on Friday, February 18th. The basic materials company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.01. The company had revenue of $213.13 million for the quarter, compared to analyst estimates of $201.00 million. Balchem had a net margin of 12.03% and a return on equity of 13.06%. During the same period in the previous year, the business earned $0.83 EPS. As a group, research analysts forecast that Balchem will post 3.22 earnings per share for the current year.
BCPC has been the subject of several research reports. Sidoti raised shares of Balchem from a “neutral” rating to a “buy” rating and set a $175.00 price target for the company in a research note on Tuesday, February 22nd. HC Wainwright lowered their price target on shares of Balchem from $170.00 to $155.00 and set a “buy” rating on the stock in a research note on Tuesday, March 8th. Zacks Investment Research downgraded shares of Balchem from a “hold” rating to a “sell” rating in a research note on Monday, March 14th. Finally, StockNews.com assumed coverage on Balchem in a research report on Thursday, March 31st. They issued a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Balchem currently has a consensus rating of “Hold” and a consensus price target of $160.50.
Balchem Company Profile (Get Rating)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
- Get a free copy of the StockNews.com research report on Balchem (BCPC)
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.